drugset / Trial / NCT05002179

Echinaforce Study to Investigate Explorative Pharmacology and Effectiveness to Prevent From Enveloped Virus Infections

NCT05002179

RandomizedParallel-groupOpen-labelPrevention

Summary

It is a single-center, randomized, open-label, phase IV study for the explorative investigation of the pharmacological mode-of-action of Echinaforce® extract in the form of Echinaforce® Chewable tablets"- Further, it is aimed to evaluate the effectiveness of the study product for the prevention and treatment of respiratory tract infections in generally healthy adults following a real-life setting. The study covers 2x2 + 1 month of prevention in 120 randomized participants following a tight sampling set-up for sensitive detection of viral infections by RT-qPCR analysis of nasal swabs and seroconversion of SARS-CoV2 IgG/IgM in serum samples.

Timeline

Start
2020-11-20
Primary completion
2021-05-29
Completion
2021-05-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Echinacea purpurea Traditional medicine (herbal / TCM) 800 mg

Indications